Overview
Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) issued its FY2026 Annual Report on 7 July 2026, outlining a revenue of ₹8,869 crore, a global footprint of 17 development and manufacturing facilities and commercial operations in more than 100 countries.
Financial Performance
The company generated ₹8,869 crore in revenue, of which approximately 66 % originated from regulated markets, underscoring its strong presence in high‑margin jurisdictions.
Segment Highlights
Piramal Pharma Solutions, the contract development and manufacturing organization, accounted for 55 % of total revenue and served over 500 global customers. The segment announced a US$90 million investment to expand sterile injectables capacity and to develop payload‑linker capabilities. Piramal Critical Care retained its No. 1 position in the U.S. sevoflurane market, completed the acquisition of the Kenalog product line, and now supplies more than 6,000 hospitals, surgical centres and clinics worldwide. Piramal Consumer Healthcare reported ₹1,274 crore in revenue, managed a portfolio of more than 25 brands, launched 31 new products and SKUs, and recorded a 24 % growth in its Power Brands segment, which contributed 52 % of the consumer healthcare turnover.
Quality & Regulatory
During FY2026 the company underwent 38 regulatory inspections, including three inspections by the U.S. Food and Drug Administration. All USFDA inspections resulted in zero Official Action Indicated (OAI) observations, reflecting the robustness of PPL’s quality systems.
Sustainability & ESG
PPL achieved a 22.6 % reduction in Scope 1 and Scope 2 greenhouse‑gas emissions relative to the FY2022 baseline, in line with its science‑based decarbonisation roadmap.
Workforce & Safety
The firm employed over 7,285 individuals globally and reported zero workplace fatalities for the fifth consecutive year, highlighting its people‑first culture and safety focus.
Associate Companies
One of PPL’s associate entities, Abbvie Therapeutics India Private Limited—a joint venture with AbbVie—has emerged as a market leader in ophthalmology therapies within India. PPL also holds a strategic minority stake in Yapan Bio Private Limited, which operates in the biologics, bio‑therapeutics and vaccine segments and contributes one manufacturing facility to the group.
Additional Information
Further business highlights and key performance metrics are available in the FY2026 infographic and the full report at https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdf.